Navigation Links
Lumenis Receives 510K Clearance for the PolyScope Disposable Flexible Endoscope

SANTA CLARA, Calif., Oct. 27 /PRNewswire/ -- Lumenis Ltd., a global developer, manufacturer and seller of laser, light-based and radiofrequency devices for surgical, aesthetic, and ophthalmic applications, announced that on September 30th, 2009 the FDA issued a 510K to Lumenis stating that the PolyScope Flexible Endoscope can now be sold in the United States.

Under this 510K, the PolyScope is indicated in flexible endoscopic procedures for diagnostic and therapeutic applications where flexible endoscopes are standard of care including:

  • Urology, including procedures involving the bladder, ureter, renal pelvis and kidney
  • Gastroenterology, including procedures of the Biliary system involving the hepatic and pancreatic ducts

The PolyScope is an evolution in flexible scope design incorporating a truly disposable endoscopic catheter system with a reusable 10,000 pixel fiber optic. This unique concept solves many of the drawbacks encountered with the use of reusable flexible scopes such as costly and frequent repairs. In addition to the expense, broken scopes create inefficiencies in case load management and staff time needed to complete the logistics of repair and replacement. Scope reprocessing and the potential for contamination is also an issue that is substantially improved with the disposable PolyScope system.

"The clearance of the PolyScope is a significant strategic milestone for the Lumenis Surgical Division," said Dov Ofer, Lumenis' President and CEO. "A strategic focus in the growth of our surgical business has been to build on our core competency in surgical laser systems by adding disposable product lines that complement our current medical applications. This initial clearance for the PolyScope further advances our leadership position in Urology where stones, tumors and strictures are treated through flexible endoscopes using our VersaPulse® holmium lasers and SlimLine(TM) fibers. Our recent entry into the endoscopic management of stones in the GI tract will also be enhanced by combining the PolyScope with our new SlimLine GI(TM) fiber. In addition, we will pursue other indications for PolyScope that will complement our laser offerings in the ENT, Gynecology and Pulmonology specialties."

The PolyScope system is easily connected to the existing endoscopic towers currently utilized by hospitals throughout the country eliminating the need for a hospital to purchase additional capital equipment in order to use the PolyScope. With a minimal investment in the reusable 10,000 pixel fiber optic and the disposable catheters, a hospital can quickly be up and running with PolyScope.

"The PolyScope not only expands our disposable product offering but provides us a unique way to get into the access and delivery market which is highly synergistic with our therapeutic laser products," commented Lloyd Diamond, Sr. VP and General Manager of Lumenis' Surgical and Vision businesses. "In addition to other benefits, there are medical safety concerns with current scopes that highlight the need for a disposable endoscopic system. Even with current reprocessing methods, tissue can be retained in the small channels of reusable scopes and transferred from patient to patient. We have see recent headlines showing that reusable scopes have been the cause of the transmission of virus such as Hepatitis. The PolyScope will eliminate these concerns as this part of the scope is disposable and thus new for every patient."

European experience with the PolyScope for use in ureteroscopy was presented at the American Urology Association annual meeting by Dr. Markus Bader. "The total cost (purchase price, maintenance and repair) of using reusable flexible ureteroscopes is high and they must be repaired on a regular basis," said Dr. Bader, Attending Physician/Associate Specialist University of Munich Hospital, Grobhadern. "I also like the fact that because it is disposable, the PolyScope is always ready and I do not have to wait for a reusable scope to be sterilized. My patients also like it when I tell them that the scope I will use has never been used on any other patient."

About Lumenis

Lumenis, the world's largest medical laser company, is a global developer, manufacturer and distributor of laser, light-based and radiofrequency devices for surgical, aesthetic and ophthalmic applications, with more than 800 employees worldwide. Lumenis has over 250 patents, over 75 FDA clearances, an installed base of over 80,000 systems and presence in over 100 countries. Lumenis endeavors to bring the finest state of the art technology products to the market, fulfilling the highest standards of excellence, quality and reliability. Consequently we are able to deliver premium value and service to our customers. Lumenis' name is derived from Latin meaning "Light of Life", highlighting the light which is the basis of our technologies used to enhance life. For more information about Lumenis and its products, please go to:

For further information contact:

    Michelle Maydan
    Director of Corporate Communications

Lumenis, its logo, VersaPulse , SlimLine and Slimline GI are trademarks or registered trademarks of the Lumenis Group of Companies.

Certain statements and information in this press release may be deemed to be "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements may include, but are not limited to, statements relating to our objectives, plans and strategies, statements that contain projections of results of operations or of financial condition and all statements (other than statements of historical facts) that address activities, events or developments that we intend, expect, project, believe or anticipate will or may occur in the future. Forward-looking statements are often characterized by the use of forward-looking terminology such as "may," "will," "expect," "anticipate," "estimate," "continue," "believe," "should," "intend," "project" or other similar words, but are not the only way these statements are identified. We have based these forward-looking statements on assumptions and assessments made by our management in light of their experience and their perception of historical trends, current conditions, expected future developments and other factors they believe to be appropriate. Any forward-looking statements in this press release are made as of the date hereof, and we undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. Forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties. Important factors that could cause actual results, developments and business decisions to differ materially from those anticipated in these forward-looking statements may be found in our most recent Annual Report on Form 20-F, including the section therein entitled "Risk Factors", as well in our reports on Form 6-K, filed with the Securities and Exchange Commission.

SOURCE Lumenis Ltd.

SOURCE Lumenis Ltd.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Lumenis Introduces Advanced Retinal Laser Delivery Technology at the 2009 American Academy of Ophthalmology Annual Meeting in San Francisco, California, USA
2. Lumenis(R) Introduces AcuPulse(TM) for Fractional Laser Treatments
3. Dr. Mark Popovsky Receives Prominent Award for Leadership in Transfusion Medicine
4. Pharmalink AB Receives Patent for Nefecon(R) Principle
5. Solos Endoscopy, Inc. Receives Additional Purchase Orders from National Cancer Institute and National Institute of Health for its MammoView(TM) Product Line
6. Ikaria Receives Award for Excellence by New Jersey Business & Industry Association
7. NASCSA Receives $200,000 Grant From Purdue Pharma L.P. to Support State Prescription Drug Monitoring Programs
8. Jennerex, Inc. Receives EMEA Orphan Drug Designation for JX-594 for the Treatment of Hepatocellular Carcinoma
9. Talecris Biotherapeutics Receives FDA Approval for PROLASTIN(R)-C
10. Solos Endoscopy, Inc. Receives Multiple Purchase Orders for its MammoView(TM) Product Line
11. WorldHeart Receives IRB Approval at First Center in the Levacor(TM) VAD BTT Clinical Trial
Post Your Comments:
(Date:10/9/2015)...  Eli Lilly and Company (NYSE: LLY ) ... rights to Locemia,s intranasal glucagon, a potential treatment for ... Intranasal glucagon, which is currently in Phase III clinical ... for severe hypoglycemia. --> ... nasal powder formulation that is delivered in an emergency ...
(Date:10/9/2015)... CHAPEL HILL, N.C. , Oct. 9, 2015 ... Pharmaceutical or Medical Device environments, corporate communications is ... external communications, corporations and professionals must continuously adjust ... the effectiveness of these adjustments is difficult, but ... to today,s communication options. ...
(Date:10/9/2015)... , Oct. 9, 2015 Regulatory affairs groups ... --> --> These specialized groups ... the plethora of global regulations pertaining to the development and ... role, regulatory groups largely rely on their own internal effectiveness ... --> --> ...
Breaking Medicine Technology:
... Minn., May 4, 2011 American Medical Systems® ... devices and therapies for male and female pelvic health, ... Ministry of Health, Labor and Welfare (MHLW) to market ... the treatment of Benign Prostatic Hyperplasia (BPH), or enlarged ...
... 4, 2011 The most recent release of Via ... decision support for advance care planning to encourage early ... treatment intent and likely outcomes. Recent ... effect that attention to planning end of life care ...
Cached Medicine Technology:
(Date:10/10/2015)... Clarkston, Metamora, Michigan (PRWEB) , ... October 10, 2015 , ... ... Up to 10% of cancer patients have an inherited gene mutation. Fortunately, knowing family ... stage. Women with certain genetic mutations have:, · up to 44% lifetime risk of ...
(Date:10/10/2015)... ... October 10, 2015 , ... Adenomyosis is ... uterus, the endometrium, grows inside the muscle layer of the uterus. It's a ... of adenomyosis are similar to the symptoms of endometriosis and may include pelvic ...
(Date:10/10/2015)... Chicago, IL (PRWEB) , ... October 10, 2015 , ... With the winter season coming ... manufacturer of low-watt heaters, Cozy Products is familiar with the problem and discusses ... a few degrees to the inside of the chicken coop in the winter, utilize a ...
(Date:10/10/2015)... ... ... have to walk with crutches for the rest of my life," said an inventor from ... that would give me more independence and freedom would be amazing. This inspired me to ... developed the STRAP IN to enable an individual to walk with crutches without having to ...
(Date:10/10/2015)... ... , ... The sixth annual cost of cybercrime study the Ponemon Institute released ... companies. The New York Times broke down some of those numbers in this ... among the companies surveyed, it only proves that regular threat assessments, penetration testing and ...
Breaking Medicine News(10 mins):
... Sales and Marketing Veteran to Drive International Retail Expansion, ... Group and New WrinkleFree Brand Line ExtensionIRVINE, Calif., Jan. ... developer and distributor of medically developed and efficacy-based skin ... mass market retail locations throughout the U.S., announced today ...
... The following statement can be attributed to Michael ... has consistently said two things: We are not ... But we have urged public policy makers to ... merger without conditions, because without conditions the merger ...
... (Nasdaq: OMCL ), a leading provider of system solutions to acute healthcare ... quarter 2008 financial results. , What: Omnicell ... webcast, When: January ... Lipps, chairman, president and chief executive officer, ...
... Maine, Jan. 21 IDEXX Laboratories, Inc. (Nasdaq: ... quarter and full-year financial results for Friday, January 30, at ... conference call beginning at 9:00 a.m. (eastern) on that day. ... through a link on the IDEXX Web site, ...
... can lead to failure, , , WEDNESDAY, Jan. 21 (HealthDay ... a common cause of kidney transplant failure may help ... polyomavirus nephropathy, which affects about 9 percent of kidney ... adults but can cause serious problems for people with ...
... CAMBRIDGE, Mass. -- Schizophrenia may blur the boundary between ... that is involved in self-reflection, and thus causing an ... brain imaging study has found. , The traditional ... and emotions that characterize the disease are caused by ...
Cached Medicine News:
Disposable tracheostomy care tray....
Disposable tracheostomy care tray....
... the Right Solution For Your Tracheostomy Care ... care tray features the latest components for ... infection control task. Designed by clinicians, these ... of each patient and caregiver. All of ...
... For Your Tracheostomy Care Needs, ,Each ... the latest components for efficient and convenient ... Designed by clinicians, these latex-free trays provide ... and caregiver. All of our trays also ...
Medicine Products: